Gossamer Bio Inc. (NASDAQ: GOSS) reported Q4 EPS of ($0.74), in-line with the analyst estimate of ($0.74).

Cash, cash equivalents and marketable securities as of December 31, 2021, were $325.2 million. As a result, we currently expect cash, cash equivalents and marketable securities, and access to our debt facility will be sufficient to fund operating and capital expenditures into the second half of 2023.

For earnings history and earnings-related data on Gossamer Bio Inc. (GOSS) click here.